false 0000925741 0000925741 2024-06-10 2024-06-10 0000925741 bcda:CommonStockParValue0001CustomMember 2024-06-10 2024-06-10 0000925741 bcda:WarrantToPurchaseCommonStockCustomMember 2024-06-10 2024-06-10
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): June 10, 2024
 
BIOCARDIA, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38999
23-2753988
(State or other jurisdiction of
incorporation)
(Commission File No.)
(IRS Employer Identification
Number)
 
320 Soquel Way
Sunnyvale, California 94085
(Address of principal executive offices)
 
(650) 226-0120
(Registrant’s telephone number, including area code)
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company  ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbols
 
Name of each exchange on which registered
Common Stock, par value $0.001
BCDA
The Nasdaq Capital Market
Warrant to Purchase Common Stock
BCDAW
The Nasdaq Capital Market
 
 
 
 
Item 8.01             Other Events.
 
During the period from April 1, 2024 to June 10, 2024, BioCardia, Inc. (the Company) sold an aggregate of 335,112 shares of its common stock at then-market prices for total gross proceeds of approximately $1.85 million under the Company’s previously disclosed At The Market Offering Agreement (the Sales Agreement). Following such sales, the Company had capacity to issue up to an additional $264,000 of shares of its common stock (the Shares) under the prospectus supplement dated December 6, 2024 related to sales under the Sales Agreement, which the Company previously filed pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-275099). For additional information regarding the Sales Agreement and the Company’s liquidity position, please see the Company’s most recent Quarterly Report on Form 10-Q filed on May 14, 2024.
 
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicitation or sale of any Shares in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
BIOCARDIA, INC.
     
Date: June 10, 2024
    
 
By:
/s/ Peter Altman, Ph.D.
    Peter Altman, Ph.D.
    President and Chief Executive Officer
 
 
 
v3.24.1.1.u2
Document And Entity Information
Jun. 10, 2024
Document Information [Line Items]  
Entity, Registrant Name BIOCARDIA, INC.
Document, Type 8-K
Document, Period End Date Jun. 10, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-38999
Entity, Tax Identification Number 23-2753988
Entity, Address, Address Line One 320 Soquel Way
Entity, Address, City or Town Sunnyvale
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94085
City Area Code 650
Local Phone Number 226-0120
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000925741
CommonStockParValue0001 Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol BCDA
Security Exchange Name NASDAQ
WarrantToPurchaseCommonStock Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrant to Purchase Common Stock
Trading Symbol BCDAW
Security Exchange Name NASDAQ
BioCardia (NASDAQ:BCDAW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more BioCardia Charts.
BioCardia (NASDAQ:BCDAW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more BioCardia Charts.